The Efficacy of Cryptolepis buchanani Oil Formulation Versus Indomethacin Solution in Symptomatic Treatment of Osteoarthritis of Knee

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001291

Enrollment

Unknown

Registered

2011-04-08

Start date

2009-02-17

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Interventions

1:Indomethacin solution 1% (w/w) (Elmetacin) applied 3 sprays/affected knee (equivalent to 0.75 ml) 4 times daily for 4 weeks

2:Cryptolepis buchanani oil formulation applied 3 sprays/affected knee (equivalent to 0.75 ml) 4 times daily for 4 weeks

Eligibility

Sex/Gender

Male

Age

25 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with unilateral or bilateral OA of the knee according to the criteria of the American College of Rheumatology for more than 3 months; 2. After discontinuation of usual medications for 7 days, the visual analog scale (VAS) score assessing pain during the most painful knee movement must be between 40-70; 3. Participants must be able to walk and give both verbal and written information regarding the study.

Exclusion criteria

Exclusion criteria: 1. an underlying inflammatory arthropathy; 2. acute or chronic gouty arthritis; 3. hyperuricemia > 9 mg/dl with or without history of gouty attack; 4. expectation of surgery in the near future; 5. recent injury in the area affected by OA of knee; 6. active inflammation of OA of knee, significant knee joint effusion; 7. intra-articular corticosteroid injections within the last 3 months; 8. continuous use of the symptomatic slow-acting drugs for osteoarthritis (SYSDOA) [e.g., glucosamine sulphate, chondroitin sulphate, diacerein, and hyaluronic acid] less than 4 months or stop using these drugs less than 6 months; 9. hypersensitivity to NSAIDs; 10. concomitant skin disease at the application site; 11. use of another topical product at the application site; 12. clinically significant abnormalities in blood chemistry and hematology; 13. pregnancy; 14. lactation; 15. malignant tumors.

Design outcomes

Primary

Measure	Time frame
Number of responders according to pain reduction;Number of responders according to patients' overall opinions on improvement;	—

Secondary

Measure	Time frame
Lequesne's functional index;Visual analog scale (VAS) score;	—

Countries

Thailand

Contacts

Public ContactNutthiya Hanprasertpong

knutthiya@gmail.com+66 53 945353

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026